Profitability
Weight: 20%
B-
62
- 5yr Avg ROIC 18.6%
- Operating Margin Trend -63.94 pp/yr
MRNA
Moderna, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
A+
94
- 5yr Avg ROE 21.9%
- 5yr Share-Count CAGR -2.5%
Growth Quality
Weight: 15%
F
8
- 5yr Revenue CAGR -42.5%
- 5yr EPS CAGR -29.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
D
37
- 5yr FCF Margin -37.9%
- 5yr FCF/NI Conversion 0.82x
Balance Sheet
Weight: 20%
C-
50
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 3.08
Stability
Weight: 15%
C+
58
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 1
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 added; 2 trimmed; 1 full exit.
- Holders
- 3
- Avg Δ position
- +87.7%
- New buys
- 0
- Full exits
- 1
- Greenblatt sold -100%
- Dalio increased +393%
- Cooperman decreased -87%